Klotho-derived Peptide 1 (56-87) (human) (trifluoroacetate salt) |
| Catalog No.GC90733 |
Un péptido disruptor de TGF-β
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Klotho-derived peptide 1 (KP1) (56-87) is a peptide derived from human Klotho protein, which has roles in disrupting TGF-β signaling.1 It binds to TGF-β receptor type 1 (TGFBR2), and TGF-β receptor type 2 (TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 (10 µg/ml) inhibits TGF-β-induced increases in fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. In vivo, KP1 (1 mg/kg per day) selectively localizes to damaged kidneys and reduces serum creatine and blood urea nitrogen levels, markers of kidney function, as well as reduces kidney fibrosis, in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *